Life Scientist > Biotechnology

UK researcher's eyes opened by biotech activity down under

15 August, 2003 by Melissa Trudinger

UK scientist and entrepreneur Prof Peter Shepherd is amazed at how much biotechnology activity there is in Australia.


AVI seeks orphan status for experimental SARS drug

15 August, 2003 by Staff Writers

US firm Avi BioPharma has asked US regulators to grant 'orphan' status to its experimental drug against the virus that causes SARS, a designation meant to provide seven years of marketing exclusivity for medicines.


Bionomics beefs financial team

15 August, 2003 by Jeremy Torr

Adelaide-based genomics biotech Bionomics has appointed a new heavy hitter to its financial team with the signing up of ex-Faulding and ex-Mayne commercialisation expert Lee Craker as new CFO.


Expat's big plans to improve Anglo-Aussie ties

15 August, 2003 by Melissa Trudinger

Expatriate Australian Dr John Sime is headed back to Australia next January, with plans to improve the links between the Australian and the British biotechnology industries.


GroPep cuts its losses to produce second-half profit

15 August, 2003 by Iain Scott

Adelaide-based GroPep has continued to shuck off the disastrous after-effects of its purchase of Biotech Australia by posting a second-half profit for 2002-03.


BresaGen announces major restructure plans

14 August, 2003 by Iain Scott

BresaGen (ASX:BGN) intends to spin off its protein pharmaceuticals business and headquarter it in the US, as part of a major restructure.


Shotgun weddings leading to useful new hybrids

14 August, 2003 by Graeme O'Neill

You're a plant geneticist, and you want to extend the range of the world's most important human food crop, rice (Oryza sativa) into cooler regions of the world.


Polartechnics eyes US capital market

14 August, 2003 by Jeremy Torr

Capitalising on the successful release of its innovative Pap smear diagnostic into the European market, Polartechnics has dipped a toe into the US investment scene with the appointment of a New York investment banker as strategic advisor.


Herbal remedy fails cholesterol test - US study

13 August, 2003 by Staff Writers

An herbal remedy derived from the mukul myrrh tree and used in India to relieve heart symptoms actually raised cholesterol levels instead of lowering them as advertised, researchers said.


Acrux claims success in Phase I anxiety trial

13 August, 2003 by Melissa Trudinger

Melbourne drug delivery company Acrux has successfully completed a Phase I clinical study for its proprietary buspirone metered-dose transdermal spray (MDTS) for the treatment of anxiety.


Eiffel to collaborate with UK asthma company

11 August, 2003 by Jeremy Torr

Melbourne biotech Eiffel Technologies has signed an agreement with a UK-based drug delivery company, Meridica, to reengineer asthma therapeutics for use in a new technology inhalation device.


Evogenix teams with UK firm Domantis

11 August, 2003 by Melissa Trudinger

EvoGenix has signed an agreement with UK-based Domantis to apply its protein evolution and optimisation technology to one of Domantis's domain antibody therapeutic leads.


West Nile lookalike gives vaccine hope

08 August, 2003 by Jeremy Torr

Researchers at the University of Queensland have developed a clone of the locally endemic Kunjin virus, and successfully trialled in mice it as a West Nile virus (WNV) vaccine.


Polartechnics ramps up for Italian job

08 August, 2003 by Jeremy Torr

Device maker Polartechnics is to focus on the Italian market for the introduction of its TruScreen cervical cancer diagnostic device, as a precursor to a major push into the European screening arena.


CSIRO licenses bio-bone

08 August, 2003 by Jeremy Torr

CSIRO has formed a strategic alliance with UK-based medical device company AorTech producing spinal disc implants, using a unique polymer developed by Melbourne researchers.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd